Item 2.02 Results of Operation and Financial Condition.

On January 11, 2021, ENDRA Life Sciences Inc. (the "Company") posted an updated investor presentation on its website at http://investors.endrainc.com. The updated investor presentation states that the Company's cash balance as of December 31, 2020 was $7.3 million. This preliminary financial information is based on information available to the Company as of the date of this Current Report on Form 8-K and is subject to the completion of the Company's year-end financial closing procedures and review by the Company's independent registered public accounting firm.

Forward-Looking Statements

All statements in this report that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "explore," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, preliminary financial information. The forward-looking statements made in this report speak only as of the date of this report, and the Company assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Item 7.01 Regulation FD Disclosure.

The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference. The updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 ENDRA Life Sciences Inc. January 2021 Investor Presentation, furnished


             herewith.

© Edgar Online, source Glimpses